ABSTRACT

Colorectal cancer (CRC) ranked as the third most frequently occurring cancer, with an estimation of 1 to 2 million new cases occurring globally every year. The high mortality rate of CRC is due to the failure of current treatment options, at present the CRC treatment mainly adopts surgery combined with radiotherapy, targeted therapy and chemotherapy. A dihydro derivative of avermectin also known as ivermectin firstly introduced in agriculture and veterinary sector, but soon it was used for the treatment of onchocerciasis and parasitic infections in humans. Ivermectin also possess certain cancer related epigenetic deregulators such as SIN3A and SIN3B, which potentially effect the cancer population. In colorectal cancer, the ivermectin cause death of certain cell lines that include SW1116 and SW480 through modulating some pathways including WNT-T cell factor or by dysfunction the mitochondria. Ivermectin affects the proliferation and growth of CRCs by playing several roles that includes functioning as an RNA helicase, activating the chlorine channel activator and as an inducer of oxidative stress. There are number of studies that have proven the antitumor effect of ivermectin. However, despite such promising results in several studies that showed that ivermectin could be used in the treatment of colorectal cancer and other cancerous treatment the passage of this drug through blood-brain hurdle could be a common problem that should be considered in future. Keywords: Colorectal cancer, Multidrug Resistance, Parasitic infection
Publication date: 01/10/2022

https://ijbpas.com/pdf/2022/October/MS_IJBPAS_2022_6514.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.10.6514